Cellular therapy in NSCLC

• Date : 10/05/2021
• 1    
  0

Challenges of performing immunotherapy trials in the UK

• Date : 07/05/2021
• 1    
  0

Impacts of COVID-19 on lung cancer diagnosis in the UK

• Date : 07/05/2021
• 0    
  0

Antibody drug conjugates in lung cancer

• Date : 22/04/2021
• 0    
  0

NSCLC biomarker testing in the UK

• Date : 22/04/2021
• 0    
  0

Clinical trials for oncogenically driven lung cancer

• Date : 22/04/2021
• 0    
  0

Immunotherapy for operable lung cancer

• Date : 22/04/2021
• 0    
  0

Novel therapies on the horizon for lung cancer

• Date : 22/04/2021
• 0    
  0

BTOG 2021 highlights: immunotherapy for mesothelioma and cardiac toxicity updates

• Date : 07/05/2021
• 0    
  0

The role of virtual consultations in cancer treatment

• Date : 07/05/2021
• 0    
  0

Immunotherapy for mesothelioma

• Date : 07/05/2021
• 0    
  0

COVID-19 and the future of lung cancer treatment in the UK

• Date : 07/05/2021
• 0    
  0

BTOG 2021 highlights: translational research in lung cancer

• Date : 22/04/2021
• 0    
  0

Update from the UK Lung Cancer Coalition (UKLCC)

• Date : 07/05/2021
• 0    
  0

Cellular therapy in solid tumors

• Date : 10/05/2021
• 0    
  0

Impact of COVID-19 on lung cancer diagnosis and outcomes in the UK

• Date : 10/05/2021
• 0    
  0

The significance of PD-L1 expression in NSCLC

• Date : 10/05/2021
• 0    
  0

Impact of the COVID-19 pandemic on lung cancer patient experience

• Date : 11/05/2021
• 0    
  0

WHO classifications for thoracic cancer

• Date : 10/05/2021
• 0    
  0

Surgical considerations in a peri-operative therapy era

• Date : 17/05/2021
• 0    
  0

Activities of the Mesothelioma Research UK Centre

• Date : 22/04/2021
• 0    
  0

MiST: PARP inhibitors for malignant mesothelioma

• Date : 22/04/2021
• 0    
  0

NERO trial: PARP inhibitors for chemosensitive NSCLC

• Date : 22/04/2021
• 0    
  0

MiST: personalized approaches to mesothelioma treatment

• Date : 22/04/2021
• 0    
  0

COVID-19 and cancer outcomes in the UK

• Date : 22/04/2021
• 0    
  0

Lung cancer patient experience in the UK

• Date : 22/04/2021
• 0    
  0

Activities of ALK Positive UK

• Date : 22/04/2021
• 0    
  0

Patient perspective: UK approval of first-line brigatinib

• Date : 22/04/2021
• 0    
  0

Being a patient with lung cancer during the COVID-19 pandemic

• Date : 22/04/2021
• 0    
  0

Findings of the Gendered Experiences of Mesothelioma Study

• Date : 22/04/2021
• 0    
  0

Antibiotics impact outcomes with pembrolizumab in NSCLC patients

• Date : 22/04/2021
• 0    
  0

Establishing the future role of surgery in lung cancer treatment

• Date : 22/04/2021
• 0    
  0

History of KRAS-targeting in clinical trials

• Date : 22/04/2021
• 0    
  0

KRYSTAL-1 and CodeBreak 100: targeting KRAS G12C in lung cancer

• Date : 22/04/2021
• 0    
  0

Recent trials of KRAS targeting and the future

• Date : 22/04/2021
• 0    
  0

Challenges of KRAS-targeting for lung cancer therapy

• Date : 22/04/2021
• 0    
  0

Highlights from BTOG 2021

• Date : 22/04/2021
• 0    
  0

Key challenges in lung cancer treatment

• Date : 22/04/2021
• 0    
  0

Inequalities in biomarker testing

• Date : 22/04/2021
• 0    
  0

Multisystem immune-related AEs with immunotherapy in NSCLC

• Date : 22/04/2021
• 0    
  0

CHEST Congress 2024

• Date : 06/10/2024
• 1439    
  0

2024 World Conference on Lung Cancer

• Date : 07/09/2024
• 2355    
  0

European Association for Bronchology and Interventional Pulmonology EABIP 2024

• Date : 14/05/2024
• 2104    
  0

19th ECFS Basic Science Conference 2024

• Date : 20/03/2024
• 1825    
  0

28e Congrès de Pneumologie de Langue Française

• Date : 26/01/2024
• 4908    
  0